Surrozen, Inc. (SRZN) Investor Relations Documents

Surrozen, Inc. (SRZN) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2026-05-27. Read in-app with summaries. First-party data.

https://surrozen.com/wp-content/uploads/2025/05/SRZN_Corporate_Presentation_May_2026_v2.pdf: Surrozen is developing multi-functional antibodies for retinal vascular disease, with an IND submission for its lead candidate SZN-8141 expected in H2 2026.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-15	Press release	Surrozen to Present at Upcoming Healthcare Investor Conference
2026-05-27	Presentation	https://surrozen.com/wp-content/uploads/2025/05/SRZN_Corporate_Presentation_May_2026_v2.pdf
2026-05-12	Press release	Surrozen to Present at Upcoming Healthcare Investor Conference
2026-05-06	Press release	Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-28	Press release	Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-03-23	Press release	Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-25	Press release	Surrozen to Present at Upcoming Healthcare Investor Conference
2026-02-23	Press release	Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-02-05	Press release	Surrozen to Present at Upcoming Healthcare Investor Conference

SRZN overview · SRZN earnings · SRZN financials · SRZN KPIs · SRZN ownership · SRZN peers · SRZN filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.